ProtAb, a Wholly Owned Subsidiary of Hadasit Bio Holdings, Receives U.S. Patent for Proximab for the Treatment of RA and Type-1 Diabetes
12/2/2008 9:49:38 AM
EIN KEREM, Israel--(BUSINESS WIRE)--ProtAb Ltd., a wholly owned subsidiary of Hadasit Bio-Holdings (TASE:HDST), announced today the receipt of an allowance of a key patent underlying its technology, an antibody called Proximab. The patent covers its structure as well as its immune and therapeutic activity against rheumatoid arthritis and Type-1 diabetes. Proximab is the basis for what will be the company’s flagship product. The company currently has a wide estate of patents registered in the United States, Australia, and European countries.
comments powered by